Zacks Small Cap Research on MSN
EDSA: Gearing up to initiate phase 2 vitiligo trial in mid-2026
EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Gearing Up for Phase 2 Vitiligo Trial in Mid-2026 Edesa Biotech, Inc.
Emily Kirkpatrick is a former associate style news editor at PEOPLE. She left PEOPLE in 2017. Vesnaandjic / Getty Images Vitiligo is a chronic disorder, often due to genetics or a change in the immune ...
- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the ...
Verywell Health on MSN
7 Common Symptoms of Vitiligo in Children and Adults
Vitiligo is an autoimmune skin disorder affecting about 1 in 100 people. It is characterized by a loss of pigment (coloring) in skin patches that appear white. Melanin is the natural pigment that ...
Penile vitiligo is characterized by patches of depigmented skin, typically appearing on the foreskin and shaft, and while it may cause aesthetic concerns, it doesn’t impair the penis’s function or ...
Vitiligo is an autoimmune condition that may cause areas of the skin to lose color. Researchers do not exactly understand why vitiligo develops. These patches may remain stable or get better, and new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results